Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion
Prolactinoma is the most frequently diagnosed pituitary tumors. Dopamine agonists (DAs) are recognized as first-line therapy; however, approximately 10% patients will develop resistance to DAs therapy. Consequently, a large number of investigations have been carried out to identify novel therapeutic...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2018-07-01
|
| Series: | Open Chemistry |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/chem-2018-0064 |
| _version_ | 1819291511356915712 |
|---|---|
| author | Liu Qian Yuan Taoyang Gao Hua Gui Songbai Zhang Yazhuo Li Chuzhong |
| author_facet | Liu Qian Yuan Taoyang Gao Hua Gui Songbai Zhang Yazhuo Li Chuzhong |
| author_sort | Liu Qian |
| collection | DOAJ |
| description | Prolactinoma is the most frequently diagnosed pituitary tumors. Dopamine agonists (DAs) are recognized as first-line therapy; however, approximately 10% patients will develop resistance to DAs therapy. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets. Recently, studies have suggested that epidermal growth factor-like domain 7 (EGFL7) can promote tumor growth, invasion, and angiogenesis. We previously reported that overexpression of EGFL7 might play a crucial role in hormone-producing pituitary adenomas. In the present study, we now demonstrated a significantly higher protein expression of EGFL7 in prolactinoma compared with the normal pituitary gland. However, inhibition of EGFL7 with anti-EGFL7 antibodies significantly reduced the proliferation and PRL secretion of rat prolactinoma MMQ cells. Notably, in vitro administration of anti-EGFL7 antibodies significantly induced MMQ cells apoptosis in a dose-dependent manner. In conclusion, our finding suggests that EGFL7 is significantly overexpressed in prolactinoma and inhibition of EGFL7 with antibodies promoted MMQ cells apoptosis and inhibited PRL secretion. Thus, EGFL7 may serve as a potential novel therapeutic target for prolactinomas. |
| first_indexed | 2024-12-24T03:39:48Z |
| format | Article |
| id | doaj.art-41821751f59d4adb9ccec1fe95bb8860 |
| institution | Directory Open Access Journal |
| issn | 2391-5420 |
| language | English |
| last_indexed | 2024-12-24T03:39:48Z |
| publishDate | 2018-07-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Chemistry |
| spelling | doaj.art-41821751f59d4adb9ccec1fe95bb88602022-12-21T17:16:56ZengDe GruyterOpen Chemistry2391-54202018-07-0116162162610.1515/chem-2018-0064chem-2018-0064Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretionLiu Qian0Yuan Taoyang1Gao Hua2Gui Songbai3Zhang Yazhuo4Li Chuzhong5Beijing Neurosurgical Institute, Capital Medical University, Beijing, 10050, ChinaBeijing Tiantan Hospital, Capital Medical University, Beijing, 10050, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, 10050, ChinaBeijing Tiantan Hospital, Capital Medical University, Beijing, 10050, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, 10050, ChinaBeijing Neurosurgical Institute, Capital Medical University, Beijing, 10050, ChinaProlactinoma is the most frequently diagnosed pituitary tumors. Dopamine agonists (DAs) are recognized as first-line therapy; however, approximately 10% patients will develop resistance to DAs therapy. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets. Recently, studies have suggested that epidermal growth factor-like domain 7 (EGFL7) can promote tumor growth, invasion, and angiogenesis. We previously reported that overexpression of EGFL7 might play a crucial role in hormone-producing pituitary adenomas. In the present study, we now demonstrated a significantly higher protein expression of EGFL7 in prolactinoma compared with the normal pituitary gland. However, inhibition of EGFL7 with anti-EGFL7 antibodies significantly reduced the proliferation and PRL secretion of rat prolactinoma MMQ cells. Notably, in vitro administration of anti-EGFL7 antibodies significantly induced MMQ cells apoptosis in a dose-dependent manner. In conclusion, our finding suggests that EGFL7 is significantly overexpressed in prolactinoma and inhibition of EGFL7 with antibodies promoted MMQ cells apoptosis and inhibited PRL secretion. Thus, EGFL7 may serve as a potential novel therapeutic target for prolactinomas.https://doi.org/10.1515/chem-2018-0064egfl7antibodyprolactinomaproliferationprl secretion |
| spellingShingle | Liu Qian Yuan Taoyang Gao Hua Gui Songbai Zhang Yazhuo Li Chuzhong Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion Open Chemistry egfl7 antibody prolactinoma proliferation prl secretion |
| title | Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion |
| title_full | Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion |
| title_fullStr | Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion |
| title_full_unstemmed | Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion |
| title_short | Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion |
| title_sort | anti egfl7 antibodies inhibit rat prolactinoma mmq cells proliferation and prl secretion |
| topic | egfl7 antibody prolactinoma proliferation prl secretion |
| url | https://doi.org/10.1515/chem-2018-0064 |
| work_keys_str_mv | AT liuqian antiegfl7antibodiesinhibitratprolactinomammqcellsproliferationandprlsecretion AT yuantaoyang antiegfl7antibodiesinhibitratprolactinomammqcellsproliferationandprlsecretion AT gaohua antiegfl7antibodiesinhibitratprolactinomammqcellsproliferationandprlsecretion AT guisongbai antiegfl7antibodiesinhibitratprolactinomammqcellsproliferationandprlsecretion AT zhangyazhuo antiegfl7antibodiesinhibitratprolactinomammqcellsproliferationandprlsecretion AT lichuzhong antiegfl7antibodiesinhibitratprolactinomammqcellsproliferationandprlsecretion |